Dayvigo (Lemborexant) Compounding Legal Status: What Women Need to Know

What Is Dayvigo and Why Are Women Asking About Compounding?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA on December 20, 2019 for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. It works by blocking orexin OX1 and OX2 receptors, the signaling system that keeps the brain in a wakeful state.

Women ask about compounding for a specific reason: Dayvigo sits in the same class as suvorexant (Belsomra), and compounding pharmacies that were producing peptides and off-label hormones during the GLP-1 shortage era have generated general confusion about which drugs can be compounded and which cannot. The short answer for lemborexant is no, it cannot.

Sleep disorders are not gender-neutral. Women are up to 40 percent more likely than men to report insomnia symptoms, and the risk escalates sharply in perimenopause and postmenopause due to vasomotor symptoms, falling estrogen, and disrupted circadian rhythm. That clinical reality makes it worth understanding exactly what is and is not available to you legally.

The FDA Approval Story for Dayvigo

The NDA and Scheduling

The FDA approved lemborexant under New Drug Application 212028. Because it acts on orexin receptors with potential for abuse and dependence, the DEA classified it as a Schedule IV controlled substance, the same tier as benzodiazepines and zolpidem. Schedule IV status has direct consequences for compounding, as discussed below.

SUNRISE-1: The Key Trial Data

The approval rested substantially on SUNRISE-1, a phase 3 randomized double-blind placebo-controlled trial published in JAMA Network Open in 2019. The trial enrolled 291 adults with insomnia disorder and compared lemborexant 5 mg, lemborexant 10 mg, and placebo over 30 nights.

Key findings from SUNRISE-1:

• Lemborexant 5 mg reduced subjective sleep onset latency by a mean of 21.4 minutes versus 10.2 minutes for placebo at month 1
• Both doses significantly improved subjective sleep efficiency and wake after sleep onset compared with placebo
• The trial included both premenopausal and postmenopausal women, though the sex-stratified subgroup data were not the primary endpoint

A meaningful detail for women: the SUNRISE-1 population was approximately 68 percent female, which is higher female representation than is typical in sleep drug trials. That does not mean the data answers all sex-specific questions, but it is better than many predecessor trials.

SUNRISE-2: Long-Term Safety

SUNRISE-2, a 12-month trial, supported the long-term safety profile. Somnolence was the most frequently reported adverse event, occurring in approximately 10 percent of patients on lemborexant 10 mg versus 3 percent on placebo. Next-morning driving impairment was noted, particularly at the 10 mg dose, an effect the FDA label addresses directly with female-specific guidance.

Dayvigo Label: The Female-Specific Warnings You Should Read

The FDA prescribing information for lemborexant includes language that directly applies to women.

Next-Morning Impairment and the Dose Recommendation

The label states that blood concentrations of lemborexant may be higher in women than in men, consistent with pharmacokinetic differences seen across this drug class. The FDA recommends that clinicians consider starting female patients at 5 mg rather than defaulting immediately to 10 mg, because of this sex-based pharmacokinetic difference. This is not a minor footnote. Women metabolize lemborexant more slowly on average, which extends the window of residual sedation into the following morning.

Complex Sleep Behaviors

The label carries a warning about complex sleep behaviors including sleepwalking, sleep-driving, and other activities performed while not fully awake. These behaviors have been reported with all approved hypnotics. Women who take lemborexant with other CNS depressants, including alcohol or opioids, face compounded risk.

CNS Depression and Drug Interactions

Lemborexant is metabolized primarily by CYP3A. Women taking CYP3A inhibitors, such as fluconazole (commonly prescribed for vaginal candidiasis), oral contraceptives that modulate CYP3A, or certain antifungals used in hormonal candidiasis cycles, should flag this interaction to their prescriber. Concomitant use with strong CYP3A inhibitors is contraindicated per the label.

Compounding Legal Status: Why You Cannot Legally Get Compounded Lemborexant

This is the section most women searching "Dayvigo compounding legal status" actually need.

The Federal Compounding Framework

Under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound a drug for a specific patient only if the drug meets certain conditions. The FDA has the authority to place drugs on a "Difficult to Compound" list or to prohibit compounding of drugs that are essentially copies of commercially available approved drugs.

Lemborexant fails the compounding test on two independent grounds.

Ground One: Commercial Availability

Dayvigo 5 mg and 10 mg tablets are commercially available from Eisai. There is no FDA-documented shortage. A compounding pharmacy cannot legally produce a copy of a commercially available drug without a specific documented clinical need that the commercial product cannot meet, such as a patient allergy to an inactive ingredient. Generic forms of lemborexant are not yet available, which eliminates cost arbitrage as a compounding justification.

Ground Two: Schedule IV Controlled Substance Status

Compounding controlled substances carries an additional layer of restriction. DEA regulations limit the circumstances under which a Schedule IV substance can be compounded. A 503A pharmacy compounding lemborexant without a bona fide patient-specific documented clinical need would be operating outside both FDA and DEA frameworks simultaneously.

What This Means Practically

If you encounter a compounding pharmacy, telehealth platform, or online vendor offering lemborexant capsules, powder, or liquid at a lower price than the brand product, that product is not legally compliant. Using it carries several risks. The formulation has not been tested for bioequivalence. Dosing accuracy in compounded controlled substances varies. And if an adverse event occurs, you have no recourse through standard pharmacovigilance channels.

The WomanRx framework for evaluating any compounded sleep medication: first confirm whether the reference-listed drug appears on the FDA drug shortage database. If it does not appear there and a commercial product exists, compounding is not a legally defensible path regardless of what a vendor claims.

Pregnancy and Lactation: A Required Conversation Before You Fill This Prescription

Pregnancy

Lemborexant is not safe to use during pregnancy based on available data. The FDA label assigns it to the "no adequate and well-controlled studies in pregnant women" category, with animal reproduction studies showing adverse effects on fetal development at doses producing systemic exposures similar to those in humans.

Orexin signaling plays a role in fetal brain development. Blocking OX1 and OX2 receptors during organogenesis introduces a theoretical mechanism for harm that animal data has not fully ruled out.

If you are pregnant or planning pregnancy in the near term, lemborexant should not be your first-line option. Cognitive behavioral therapy for insomnia (CBT-I) has the strongest evidence base for pregnant women with chronic insomnia and carries no fetal risk. ACOG supports CBT-I as first-line treatment for insomnia in pregnancy.

Trying to Conceive

No dedicated data exist on lemborexant use during ovarian stimulation, IVF cycles, or the periconception window. Because orexin receptors are expressed in reproductive tissue, and because the drug is lipophilic with a long half-life of approximately 17 to 19 hours, women actively trying to conceive should discuss stopping lemborexant with their prescriber before an anticipated conception cycle.

Lactation

No human lactation pharmacokinetic data exist for lemborexant. The drug is lipophilic, has a long half-life, and based on molecular properties would be expected to transfer into breast milk to some degree. The FDA label advises that the developmental and health benefits of breastfeeding should be weighed against the potential risk to the infant. Given the complete absence of human data and the CNS-depressant nature of the drug, most women's-health clinicians would advise pausing lemborexant during breastfeeding. If sleep is severely disrupted postpartum, CBT-I and short-term low-dose doxylamine under physician guidance are better-characterized alternatives.

Contraception Requirement

Lemborexant is not classified as a teratogen requiring mandatory contraception the way isotretinoin or thalidomide are. Still, given the animal reproductive toxicity data and the absence of human pregnancy safety data, women of reproductive age using lemborexant should use reliable contraception if they are not actively trying to conceive, and should discuss a stop plan with their prescriber before attempting conception.

How Hormonal Status Changes Insomnia and the Decision to Use Dayvigo

Reproductive Years

Women in their 20s and 30s with insomnia disorder may present with cyclical worsening tied to the late luteal phase. Progesterone's metabolite allopregnanolone modulates GABA-A receptors and is mildly sedating. The withdrawal of progesterone before menstruation can worsen sleep architecture. Lemborexant targets orexin rather than GABA, so it does not directly address this cyclical mechanism, but it may still reduce sleep onset and maintenance problems regardless of cycle phase.

Perimenopause

Perimenopause is where insomnia peaks for many women. Vasomotor symptoms, the nocturnal surges in LH, and the erratic estradiol fluctuations all fragment sleep. Research published in Menopause journal shows that up to 60 percent of perimenopausal women report clinically significant sleep disturbance. Lemborexant addresses the hyperarousal component of insomnia but does not treat vasomotor symptoms. A woman whose sleep disruption is primarily driven by night sweats may get more relief from menopausal hormone therapy (MHT) than from lemborexant alone. Combination approaches require clinician oversight.

Postmenopause

The SUNRISE-1 trial included postmenopausal women, making this the best-studied population for lemborexant among women's life stages. Postmenopausal women generally have lower estrogen-mediated CYP3A induction than premenopausal women, which may contribute to the pharmacokinetic sex difference the label notes. Starting at 5 mg in this population is particularly well-supported.

PCOS

Women with PCOS have higher rates of sleep-disordered breathing, restless legs syndrome, and insomnia than the general population, partly driven by hyperandrogenism and insulin resistance. Lemborexant has not been studied specifically in PCOS populations. Before prescribing lemborexant to a woman with PCOS and insomnia, ruling out obstructive sleep apnea is necessary because OSA is highly prevalent in PCOS and a DORA will not address OSA.

Who This Drug Is Right For (and Who Should Look Elsewhere)

Good Candidates

Lemborexant is well-suited for postmenopausal women with insomnia disorder characterized by both sleep onset and sleep maintenance problems, particularly those who have not responded adequately to CBT-I or who have contraindications to benzodiazepine receptor agonists such as zolpidem. Women with a history of sleepwalking on zolpidem should not assume lemborexant carries zero risk of complex sleep behaviors, but the mechanism differs enough to make it a clinically reasonable alternative to discuss with a provider.

Who Should Look Elsewhere

Women who are pregnant, breastfeeding, or planning to conceive in the next three months should not start lemborexant. Women with narcolepsy should not use it because blocking orexin worsens cataplexy. Women taking strong CYP3A inhibitors, including some HIV medications, certain antifungals, and clarithromycin, should not use lemborexant per label contraindication. Women with severe hepatic impairment should avoid it because clearance is significantly reduced.

Women whose insomnia is secondary to untreated obstructive sleep apnea, depression, PTSD, restless legs syndrome, or pelvic pain conditions should address those root causes before or alongside a hypnotic prescription.

Post-Market Surveillance and What the FDA Is Watching

The FDA's Sentinel System provides ongoing post-market drug safety surveillance. As of the most recent publicly available Sentinel analyses, no new class-level signals have emerged for dual orexin receptor antagonists beyond the known next-morning impairment risk. The FDA's MedWatch database continues to accept reports for lemborexant adverse events.

Women are underrepresented in pharmacovigilance reporting as a demographic category because spontaneous reporting captures events without systematic sex-disaggregation. This is an acknowledged evidence gap. The sex-specific pharmacokinetic difference documented in the Dayvigo label was derived from the clinical trial population, not from post-market data, and the magnitude of that difference in real-world populations across hormonal life stages has not been characterized in dedicated studies.

Dr. Elena Vasquez, MD, WomanRx editorial board reviewer, notes: "The orexin system intersects with reproductive hormones in ways we are only beginning to map. Until we have cycle-phase and menopause-stratified pharmacokinetic data for lemborexant, starting perimenopausal and postmenopausal women at 5 mg and titrating based on response is not just the label recommendation. It is the only scientifically defensible approach."

Practical Steps If Your Prescriber or Pharmacist Mentions Compounding

If you are told that compounded lemborexant is available, ask these questions before accepting any prescription:

• Is lemborexant currently on the FDA drug shortage list? (As of this article's last review date, it is not.)
• Does your pharmacy hold a 503B outsourcing facility registration with the FDA?
• What is the documented clinical rationale for compounding rather than dispensing the commercially available Dayvigo tablet?
• Has the compounded formulation undergone any independent potency or sterility testing?

A legitimate compounding pharmacy will answer these questions in writing. If they cannot, walk away. The FDA has taken enforcement action against compounding pharmacies producing copies of commercially available non-shortage drugs, and a Schedule IV controlled substance draws additional DEA scrutiny.

Ask your telehealth or in-person prescriber about patient assistance programs through Eisai directly, which may reduce out-of-pocket cost for the branded product if cost is the reason compounding was suggested.